Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Ifebemtinib by Inxmed (Nanjing) for Non-Small Cell Lung Cancer: Likelihood of Approval
Ifebemtinib is under clinical development by Inxmed (Nanjing) and currently in Phase II for Non-Small Cell Lung Cancer. According to...
Ifebemtinib by Inxmed (Nanjing) for Non-Small Cell Lung Cancer: Likelihood of Approval
Ifebemtinib is under clinical development by Inxmed (Nanjing) and currently in Phase II for Non-Small Cell Lung Cancer. According to...
Ifebemtinib by Inxmed (Nanjing) for Metastatic Colorectal Cancer: Likelihood of Approval
Ifebemtinib is under clinical development by Inxmed (Nanjing) and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData,...
Ifebemtinib by Inxmed (Nanjing) for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Ifebemtinib is under clinical development by Inxmed (Nanjing) and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...
Ifebemtinib by Inxmed (Nanjing) for Ovarian Cancer: Likelihood of Approval
Ifebemtinib is under clinical development by Inxmed (Nanjing) and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase...
Ifebemtinib by Inxmed (Nanjing) for Metastatic Pancreatic Cancer: Likelihood of Approval
Ifebemtinib is under clinical development by Inxmed (Nanjing) and currently in Phase II for Metastatic Pancreatic Cancer. According to GlobalData,...
Ifebemtinib by Inxmed (Nanjing) for Small-Cell Lung Cancer: Likelihood of Approval
Ifebemtinib is under clinical development by Inxmed (Nanjing) and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData,...